Acadia Pharmaceuticals (ACAD) PT Lowered to $39 at Mizuho, 'Daybue Seasonality Trend May Raise Concerns'
Tweet Send to a Friend
Mizuho Securities analyst Uy Ear lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $39.00 (from $40.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
